Study Links Frequent Cannabis Use to Higher Waking Cortisol Levels

Study Design and Cortisol Measurement Protocol

The observational study measured salivary cortisol at four time points—immediately upon waking, then at 15, 30, and 45 minutes—across 58 participants divided into frequent-use and control cohorts. Researchers defined frequent use as self-reported cannabis consumption at least four days per week for the prior six months. Controls reported no cannabis use in the same window.

Participants collected saliva samples at home on two consecutive weekdays. Cortisol concentrations were analyzed via enzyme immunoassay at a university endocrinology lab. Excluded: individuals with diagnosed endocrine disorders, current use of corticosteroids, or shift-work schedules that disrupt circadian rhythm.

Waking Cortisol Elevated; Awakening Response Unchanged

Frequent cannabis users showed a mean waking cortisol level 22% higher than controls (12.4 nmol/L vs. 10.2 nmol/L), a difference that reached statistical significance (p = 0.031). The cortisol awakening response—the rate and magnitude of the hormone's rise in the first 30 minutes—didn't differ between groups. Both cohorts exhibited the expected CAR curve, peaking around 30 minutes post-wake.

The data suggest frequent cannabis use correlates with a higher cortisol baseline at the moment of waking but doesn't flatten or exaggerate the physiological stress-response arc that follows. Study authors noted that elevated waking cortisol has been associated in prior literature with chronic stress states, though they emphasized the cross-sectional design precludes causal inference.

Limitations and Confounding Variables

The study didn't control for THC potency, consumption method, or time of last use before the sampling window, all variables known to influence endocannabinoid-HPA axis interactions. Self-reported frequency is subject to recall bias. The sample size of 58 participants limits statistical power for subgroup analysis by sex, age, or consumption pattern.

No blood or urine cannabinoid assays were performed to verify recency or cumulative exposure. Reverse causation can't be ruled out—individuals with pre-existing elevated cortisol may self-medicate with cannabis. For full background on cortisol and cannabis endocrinology, see the CannIntel topic hub on Cannabis Cortisol and Stress Research.

Implications for Medical Cannabis Protocols

Clinicians advising medical cannabis patients on stress-related conditions may need to monitor baseline cortisol, particularly in chronic-use cases where the HPA axis is already dysregulated. The finding doesn't contradict the acute anxiolytic effects of cannabinoids documented in controlled trials. It does raise questions about long-term homeostatic adaptation.

State medical cannabis programs don't currently require endocrine screening as part of patient certification. If the association holds in larger longitudinal cohorts, regulatory frameworks may eventually mandate cortisol monitoring for patients using cannabis daily for anxiety or PTSD—conditions already characterized by HPA dysfunction.

Watch for replication studies with objective cannabinoid biomarkers and longitudinal cortisol tracking to distinguish acute from chronic effects.